Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study.
Authors:
Iacoviello L, Agnoli C, De Curtis A, di Castelnuovo A, Giurdanella MC, Krogh V, Mattiello A, Matullo G, Sacerdote C, Tumino R, Vineis P, de Gaetano G, Panico S, Donati MB.
Source:
BMJ Open 2013; 3: e003725. doi: 10.1136/bmjopen-2013-003725.